Adaptive Biotechnologies (ADPT) Operating Expenses (2018 - 2026)

Adaptive Biotechnologies has disclosed Operating Expenses across 9 years of filings, most recently posting $90.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $90.1 million, up 9.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $342.1 million (up 2.77% YoY), and the FY2025 annual result was $334.1 million, down 2.17% from the prior year.
• Operating Expenses came in at $90.1 million for Q1 2026 at Adaptive Biotechnologies, up from $84.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $116.9 million in Q4 2023 to a low of $79.1 million in Q3 2024.
• The 5-year median for Operating Expenses is $90.5 million (2024), against an average of $91.1 million.
• Across the five-year window, Operating Expenses gained 27.55% in 2022 and plunged 30.43% in 2024, its largest moves.
• Adaptive Biotechnologies' Operating Expenses stood at $94.4 million in 2022, then advanced by 23.8% to $116.9 million in 2023, then slumped by 30.43% to $81.3 million in 2024, then gained by 3.88% to $84.5 million in 2025, then gained by 6.66% to $90.1 million in 2026.
• The last three Operating Expenses figures came in at $90.1 million (Q1 2026), $84.5 million (Q4 2025), and $83.7 million (Q3 2025), per Business Quant data.